Allergy Asthma Immunol Res.  2017 Jul;9(4):340-346. 10.4168/aair.2017.9.4.340.

Macrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea

Affiliations
  • 1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea. djsong506@korea.ac.kr
  • 2Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea.
  • 3Nanobiosys Inc., Seoul, Korea.
  • 4Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, Seoul, Korea.

Abstract

PURPOSE
The aim of this study was to investigate the change in macrolide resistance rate in pediatric Mycoplasma pneumoniae pneumonia and to evaluate the influence of macrolide-resistant M. pneumoniae (MRMP) on the clinical course of disease, by comparing 2 recent, consecutive epidemics in Korea.
METHODS
A total of 250 patients with M. pneumoniae pneumonia admitted to a single tertiary hospital were enrolled in this study. Detection of MRMP was based on specific point mutations in domain V of the 23S rRNA gene. The medical records of enrolled patients were reviewed retrospectively, and the clinical courses and laboratory data were compared.
RESULTS
The macrolide resistance rate of M. pneumoniae was 51.1% (48/94) in the 2011 epidemic, and 87.2% (136/156) in the 2015 epidemic. All MRMP isolates had the A2063G point mutation. In comparison of 2 epidemics, the mean age of patients with M. pneumoniae pneumonia was increased, and the total febrile days and febrile days after initiation of macrolides were prolonged in the 2015 epidemic. Overall severity of MRMP or macrolide-susceptible M. pneumoniae (MSMP) pneumonia over 2 epidemics was not significantly changed. However, the proportion of patients who had a fever lasting more than 72 hours after initiation of macrolides and who received corticosteroid treatment were higher in MRMP pneumonia during 2 epidemics.
CONCLUSIONS
The macrolide resistance rate of M. pneumoniae has risen rapidly over 2 recent, consecutive epidemics, and this has been associated with a prolonged clinical course and increased use of corticosteroids to treat pediatric M. pneumoniae pneumonia.

Keyword

Drug resistance; macrolides; Mycoplasma pneumoniae

MeSH Terms

Adrenal Cortex Hormones
Child*
Drug Resistance
Fever
Genes, rRNA
Humans
Korea*
Macrolides
Medical Records
Mycoplasma pneumoniae
Pneumonia*
Pneumonia, Mycoplasma
Point Mutation
Retrospective Studies
Tertiary Care Centers
Adrenal Cortex Hormones
Macrolides

Figure

  • Figure Study population. MRMP, macrolide-resistant M. pneumoniae; MSMP, macrolide-susceptible M. pneumoniae; PCR, polymerase chain reaction.


Cited by  4 articles

Current usage and effects of steroids in the management of childhood mycoplasma pneumonia in a secondary hospital
Susie Yoo, Seong Eun Choi, Jiyoung Chun, Yo Han Ahn, Ky Young Cho, Yong Ju Lee, Tae Jung Sung, Kon Hee Lee
Allergy Asthma Respir Dis. 2018;6(2):122-127.    doi: 10.4168/aard.2018.6.2.122.

Related factors for and changes in clinical manifestations in mycoplasma pneumonia nonresponsive to macrolide treatment
Chih-Lung Tang, In Kyung Ryu, Ji-Hyun Jung, Jin-Sung Park, Hyo-Bin Kim
Allergy Asthma Respir Dis. 2018;6(2):116-121.    doi: 10.4168/aard.2018.6.2.116.

Literature review and future strategies of childhood respiratory diseases in Korea
Man Yong Han, Hai Lee Chung, Young Min Ahn, Jung Yeon Shim
Allergy Asthma Respir Dis. 2018;6(Suppl 1):S66-S76.    doi: 10.4168/aard.2018.6.S1.S66.

Genetic Variation in Mycoplasma genitalium
Gilho Lee
Urogenit Tract Infect. 2017;12(2):65-76.    doi: 10.14777/uti.2017.12.02.65.


Reference

1. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008; 32:956–973. PMID: 18754792.
2. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm. 2009; 15:S5–S11.
Article
3. Ferwerda A, Moll HA, de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001; 160:483–491. PMID: 11548186.
4. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010; 16:78–86. PMID: 20094751.
5. Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother. 2012; 56:1108–1109. PMID: 22106216.
6. Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis. 2013; 19:1281–1284. PMID: 23876792.
7. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006; 50:709–712. PMID: 16436730.
8. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008; 52:348–350. PMID: 17954691.
9. Kim EK, Youn YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr. 2015; 58:172–177. PMID: 26124847.
10. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect. 2003; 9:263–273. PMID: 12667235.
11. Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis. 1996; 173:1445–1452. PMID: 8648218.
12. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology. 2012; 17:354–362. PMID: 22077195.
13. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1995; 39:2770–2773. PMID: 8593017.
14. Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis. 2012; 12:126. PMID: 22650321.
Article
15. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother. 2008; 52:3542–3549. PMID: 18644962.
16. Seo YH, Kim JS, Seo SC, Seo WH, Yoo Y, Song DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr. 2014; 57:186–192. PMID: 24868216.
17. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother. 2009; 53:2158–2159. PMID: 19273685.
18. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013; 57:4046–4049. PMID: 23716043.
19. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther. 2008; 6:509–521. PMID: 18662117.
20. Cheong KN, Chiu SS, Chan BW, To KK, Chan EL, Ho PL. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect. 2016; 49:127–130. PMID: 25556047.
21. Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014; 58:1034–1038. PMID: 24277047.
22. Shin JE, Cheon BR, Shim JW, Kim DS, Jung HL, Park MS, et al. Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma. Korean J Pediatr. 2014; 57:271–277. PMID: 25076972.
23. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006; 41:263–268. PMID: 16437541.
24. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res. 2014; 6:22–26. PMID: 24404389.
25. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014; 49:377–380. PMID: 23401275.
26. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001; 45:617–620. PMID: 11592636.
27. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, et al. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J. 2011; 37:1522–1524. PMID: 21632830.
28. Dumke R, Stolz S, Jacobs E, Juretzek T. Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis. 2014; 29:197–199. PMID: 25449256.
Full Text Links
  • AAIR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr